☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - July 2024

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Empagliflozin (Jardiance®) has been accepted for restricted use in adults for the treatment of chronic kidney disease. The restriction limits use to patients on individually optimised standard care (with ACEi or ARB) and, at the start of treatment, either:

  • an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73m2 up to 45 mL/min/1.73m2, or
  • an eGFR of 45 mL/min/1.73m2 up to 90 mL/min/1.73m2 and either:
    • A urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more, or
    • Type 2 Diabetes Mellitus

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - July 2024' by emailShare 'SMC Update - July 2024' on FacebookShare 'SMC Update - July 2024' on TwitterShare 'SMC Update - July 2024' on MastodonShare 'SMC Update - July 2024' on LinkedInShare 'SMC Update - July 2024' on reddit


No Comments to “SMC Update - July 2024”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.